Effects of short-term antiestrogen treatment of primary breast cancer on estrogen receptor mRNA and protein expression and on estrogen-regulated genes

Breast Cancer Research and Treatment

Volumn 41, Issue 1, 1996, Pages 31-41

  McClelland, Richard A ^a   Manning, David L ^a   Gee, Julia M W ^a   Anderson, Elizabeth ^b   Clarke, Robert ^b   Howell, Anthony ^b   Dowsett, Mitchell ^c   Robertson, John F R ^d   Blamey, Roger W ^d   Wakeling, Alan E ^e   Nicholson, Robert I ^a,f  

^a Tenovus Cancer Research Centre   (United Kingdom)

^b CHRISTIE HOSPITAL   (United Kingdom)

^c ROYAL MARSDEN HOSPITAL   (United Kingdom)

^d NOTTINGHAM CITY HOSPITAL   (United Kingdom)

^e ASTRAZENECA   (United Kingdom)

^f CARDIFF UNIVERSITY   (United Kingdom)

Author keywords

Antiestrogen; Breast cancer; Estrogen receptor; Estrogen regulated genes

Indexed keywords

ACTIN; ANTIESTROGEN; ESTROGEN; ESTROGEN RECEPTOR; FULVESTRANT; MESSENGER RNA; TAMOXIFEN;

ARTICLE; BREAST BIOPSY; BREAST CANCER; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; FEMALE; GENE EXPRESSION REGULATION; GENETIC TRANSCRIPTION; HUMAN; HUMAN TISSUE; IMMUNOCYTOCHEMISTRY; INTRAMUSCULAR DRUG ADMINISTRATION; MASTECTOMY; NORTHERN BLOTTING; PHASE 1 CLINICAL TRIAL; PREOPERATIVE TREATMENT; PRIORITY JOURNAL; PROTEIN EXPRESSION; RANDOMIZED CONTROLLED TRIAL; RNA HYBRIDIZATION;

ANTINEOPLASTIC AGENTS, HORMONAL; BREAST NEOPLASMS; ESTRADIOL; ESTROGEN ANTAGONISTS; ESTROGENS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOHISTOCHEMISTRY; NEOPLASM PROTEINS; NEOPLASMS, HORMONE-DEPENDENT; PROTEINS; RECEPTORS, ESTROGEN; RNA, MESSENGER; TAMOXIFEN; TUMOR SUPPRESSOR PROTEINS;

EID: 10244278009     PISSN: 01676806     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF01807034     Document Type: Article

References (38)

1. Manning DL, Nicholson RI, Eaton CL: Role of oestrogens and growth factors in the aetiology of breast cancer. In: Lincoln DW, Edwards CRW (eds) Recent Advances in Endocrinology and Metabolism, Vol 4. Churchill Livingstone, London, 1992, pp 133-149
2. Nicholson RI, Francis AB, McClelland RA, Manning DL, Gee JMW: Pure anti-oestrogens (ICI 164384 and ICI 182780) and breast cancer: is the attainment of complete oestrogen withdrawal worthwhile? Endocrine-Related Cancer 3: 1-13, 1994
3. Jordan VC: A current view of tamoxifen tor the treatment and prevention of breast cancer. Br J Pharmacol 110: 507-517, 1993
4. Saez RA, Osborne CK: Hormonal treatment of advanced breast cancer. In: Kennedy BJ (ed) Current Clinical Oncology. Alan R. Liss., New York, 1989, pp 163-172
5. Early Breast Cancer Trialists' Collaborative Group: Effects of adjuvant tamoxifen and of cytotoxic therapy on mortality in early breast cancer: an overview of 61 randomized trials among 28,896 women. N Engl J Med 319: 1681-1692, 1988
6. Powles TJ, Tillyer CR, Jones AL: Prevention of breast cancer with tamoxifen: an update on the Royal Marsden Hospital Pilot Program. Eur J Cancer 26: 680-684, 1990
7. Wolf DM, Jordan VC: Drug resistance to tamoxifen during breast cancer therapy. Breast Cancer Res Treat 27: 27-40, 1993
8. Osborne CK, Coronado-Heinsohn EB, Hilsenbeck SG, McCue BL, Wakeling AE, McClelland RA, Manning DL, Nicholson RI: Pure steroidal antiestrogens are superior to tamoxifen in a model of human breast cancer. JNCI 87: 746-750, 1995
9. Nicholson RI, Gee JMW, Eaton CL, Manning DL, Mansel RE, Sharma AK, Douglas-Jones A, Price-Thomas M, Howell A, DeFriend DJ, Bundred NJ, Anderson E, Robertson JFR, Blamey RW, Dowsett M, Walton P, Wakeling AE: Pure anti-estrogens in breast cancer: experimental and clinical observations. In: Motta M, Serio M (eds) Sex Hormonesand Anti-Hormones in Endocrine Dependent Pathology: Basic and Clinical Aspects. Elsevier Science, Amsterdam, 1994, pp 347-360
10. Wakeling AE, Newboult E, Peters SW: Effects of anti-oestrogens on the proliferation of MCF-7 human breast cancer cells. J Mol Endocrinol 2: 225-234, 1989
11. Nicholson RI: Pure antioestrogens and the therapy of breast cancer. In: Current Directions in Cancer Chemotherapy. IBC Technical Services, London, 1992, pp 1-5
12. Wakeling AE, Bowler J: Novel antioestrogens without partial agonist activity. J Steroid Biochem 31: 645-653, 1988
13. Wakeling AE, Dukes M, Bowler J: A potent specific pure antiestrogen with clinical potential. Cancer Res 51: 3867-3873, 1991
14. Lykkesfeldt AE, Sorensen EK: Effect of estrogen and antiestrogens on cell proliferation and synthesis of secreted proteins in the human breast cancer cell line MCF7 and a tamoxifen resistant variant subline. Acta Oncologica 31: 131-138, 1992
15. Wakeling AE: The future of pure antioestrogens in clinical breast cancer. Breast Cancer Res Treat 25: 1-9, 1993
16. Nicholson RI, Walker KJ, Bouzubar N, Wills R, Gee JMW, Rushmere NK, Davies P: Estrogen deprivation in breast cancer: clinical, experimental and biological aspects. Annals of the New York Academy of Sciences 595: 316-327, 1990
17. Manning DL, McClelland RA, Bryant S, Knowlden J, Gee JMW, Francis AB, Robertson JFR, Blamey RW, Sutherland RL, Ormandy CJ, Mansel RE, Nicholson RI: Oestrogen-regulated genes in breast cancer: role in prognosis and endocrine sensitivity. Acta Oncol 641-646, 1995
18. DeFriend DJ, Howell A, Nicholson RI, Anderson E, Dowsett M, Mansel RE, Blamey RW, Bundred NJ, Robertson JR, Saunders C, Baum M, Wallon P, Sutcliffe F, Wakeling AE: Investigation of a new pure antiestrogen (ICI 182780) in women with primary breast cancer. Cancer Res 54: 408-414, 1994
19. Gibson MK, Nemmers LA, Beckman LA, Beckman WC, Davies VL, Curtis SW, Korach KS: The mechanism of ICI164384 antioestrogenicity involves rapid loss of estrogen receptor in uterine tissue. Endocrinology 129: 2000-2010, 1991
20. Fawell SE, White R, Hoare S, Sydenham M, Page M, Parker MG: Inhibition of estrogen receptor DNA binding by the pure antiestrogen ICI 164384 appears to be mediated by receptor dimerization. Proc Natl Acad Sci USA 87: 6883-6887, 1990
21. Clarke RB, Laidlaw IJ, Jones LJ, Howell A, Anderson E: Effect of tamoxifen on Ki67 labelling index in human breast tumours and its relationship to oestrogen and progesterone receptor status. Br J Cancer 67: 606-611, 1993
22. Kiang DT, Kollander RE, Thomas T, Kennedy BJ: Upregulation of estrogen receptors by non-steroidal antiestrogens in human breast cancer. Cancer Res 49: 5312-5316, 1989
23. Howell A, Harland RNL, Barnes DM, Baildam AD, Wilkinson MJS, Hayward E, Swindell R, Sellwood RA: Endocrine therapy for advanced carcinoma of the breast: relationship between the effect of tamoxifen on concentrations of progesterone receptor and subsequent response to treatment. Cancer Res 47: 300-304, 1987
24. Manning DL, Robertson JFR, Ellis IO, Elston CW, McClelland RA, Gee JMW, Jones RJ, Green CD, Cannon P, Blarney RW, Nicholson RI: Oestrogen-regulated genes in breast cancer: association of pLIV1 with lymph node involvement. Eur J Cancer 30A: 675-678, 1994
25. Masiakowski P, Breathnach R, Bloch J, Gannon F, Krust A, Chambon P: Cloning of cDNA sequences of hormone regulated genes from the MCF7 human breast cancer cell line. Nucl Acids Res 10: 7895-7903, 1983
26. Walker KJ, McClelland RA, Candlish W, Blamey RW, Nicholson RI: Heterogeneity of oestrogen receptor expression in normal and malignant breast tissue. Eur J Cancer 28: 34-37, 1992
27. McClelland RA, Finlay P, Walker KJ, Nicholson D, Robertson JFR, Blamey RW, Nicholson RI: Automated quantitation of immunocytochemically localized estrogen receptors in human breast cancer. Cancer Res 50: 3545-3550, 1990
28. Manning DL, Daly RJ, Lord PG, Kelly KF, Green CD: Effects of estrogen on the expression of a 4.4 kb mRNA in the ZR75-1 human breast cancer cell line. Mol Cell Endocrinol 59: 205-212, 1988
29. Manning DL, McClelland RA, Gee JMW, Chan CMW, Green CD, Blamey RW, Nicholson RI: The role of four oestrogen-responsive genes, pLIV1, pS2, pSYD3 and pSYD8, in predicting responsiveness to endocrine therapy in primary breast cancer. Eur J Cancer 29A: 1462-1468, 1993
30. Barrett-Lee PJ, Travers MT, McClelland RA, Luqmani Y, Coombes RC: Characterization of estogen receptor messenger RNA in human breast cancer. Cancer Res 47: 6653-6659, 1987
31. Dauvois S, Danielian PS, White R, Parker MG: Antiestrogen ICI164384 reduces cellular estrogen receptor content by increasing its turnover. Proc Natl Acad Sci USA 89: 4037-4041, 1992
32. Dowsett M, Howell R, Salter J et al.: Effects of the pure antioestrogen ICI 182780 on oestrogen receptors, progesterone receptors and Ki67 antigen in human endometrium in vivo. Human Reprod 10: 262-267, 1995
33. Brown AM, Jeltsch JM, Roberts M, Chambon P: Activation of pS2 gene transcription is a primary response to estrogen in the human breast cancer cell line MCF7. Proc Natl Acad Sci USA 81: 6344-6348, 1984
34. Phillips A, Chalbos D, Rochefort H: Estradiol increases and anti-estrogens antagonise the growth factor-induced activator protein-1 activity in MCF-7 breast cancer cells without affecting c-fos and c-jun synthesis. J Biol Chem 268: 14103-14108, 1993
35. Nicholson RI, Gee JMW, Francis AB, Manning DL, Wakeling AE, Katzenellenbogen BS: Observations arising from the use of pure antiestrogens on estrogen-responsive (MCF-7) and estrogen growth-independent (K3) human breast cancer cells. Endocrine-Related Cancer 2: 115-121, 1995
36. Berry M, Metzger D, Chambon P: Role of the two activating domains of the oestrogen receptor in the cell-type and promoter-context dependent agonistic activity of the anti-oestrogen 4-hydroxytamoxifen. EMBO J 9: 2811-2818, 1990
37. Wiseman LR, Johnson MD, Wakeling AE, Lykkesfeldt AE, May FEB, Wesley BR: Type 1 IGF receptor and acquired tamoxifen resistance in estrogen-responsive human breast cancer cells. Eur J Cancer 29: 2256-2264, 1993
38. DeFriend DL, Blamey RW, Robertson JF, Walton P, Howell A: Response to the pure antiestrogen ICI182780 after tamoxifen failure in advanced breast cancer. Breast Cancer Res Treat 27: Abstract 21, p 136, 1993